Achievement of a normal FLC ratio (FLCr) following treatment indicates hematologic response and suggests better outcomes in light chain amyloidosis (AL). We examined if elevated involved free light chain (hiFLC) impacts outcomes in patients achieving normal FLCr. We retrospectively analyzed 345 AL patients who were diagnosed within a 10-year period (2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015) 
| I N TR ODU C TI ON
Amyloidosis is a rare systemic disease encompassing a heterogeneous group of disorders characterized by the deposition of protein fibrils in various organ and tissues. 1 
| Statistical analysis
Categorical variables were analyzed using chi-square and Fisher's exact test and continuous variables using Kruskal-Wallis test and Wilcoxon rank sum test. The progression free survival (PFS) was calculated from the date of diagnosis to the date of start of second line treatment or progression mandating treatment or death, whichever occurs first. The overall survival (OS) was calculated from the date of diagnosis till death from any cause or the date of last follow up. The PFS and OS curves were generated using the Kaplan-Meier method and differences between survival curves were tested for statistical significance using the two-sided log-rank test. Multivariate analyses were performed using the Cox proportional hazards model. All reported p values were two sided at the conventional 5% significance level. Data were analyzed with JMP version 12 and SAS version 9.4 software (SAS Inc., Cary, NC, USA). comparison of the patients with hiFLC1 and non-hiFLC1 is also provided in Table 1 , along with baseline characteristics and details of treatment as well as the number of patients with available data. We also compared the baseline characteristics of patients with hiFLC2 and nonhiFLC2 and the data is presented in Supporting Information Table S1 . Figure 1B ). In addition, we performed a more stringent comparison for difference in survival between patients with hiFLC2 and non-hiFLC2. We found that the median PFS in patients who had hiFLC2 was lower than for those with non-hiFLC2 variables. We found that the poor prognostic impact of hiFLC1 and hiFLC2 on PFS and OS was independent of the above-mentioned variables, as shown in Table 2 . 
| RE S U L TS

| D I SCUSSION
The impact of hiFLC in patients with normal FLC ratio on ongoing amyloid formation and hence on outcomes of patients with systemic AL is not well documented. Our study showed that patients with AL who has hiFLC after initial therapy had higher rates of cardiac, hepatic and multi-organ involvement and higher proportion of patients in advanced
Mayo 2012 stage at diagnosis. We also demonstrated that persistent elevation of iFLC predicts worse PFS and OS even among those who achieved normal FLC ratio after initial therapy. This poor prognostic impact of hiFLC on survival was found to be independent of serum creatinine on multivariate analysis.
The therapeutic approach in AL largely relies on the ability of the treatment provided to stop the production of the monoclonal FLC which in turn may stop and possibly reverse the end-organ dysfunction.
The serum FLC assay does not distinguish between monoclonal and polyclonal FLCs. The higher (or lower) the j to k ratio, the more likely it is that a monoclonal gammopathy exists. Hence, the FLC ratio is considered to be more appropriate as compared to the absolute FLC values for response assessment of patients with AL. However, it should be noted that the normalization of FLC ratio after therapy may be achieved with normal, low or high absolute level of iFLC.
Previous studies have demonstrated that the absolute level of iFLC or the difference of the involved and uninvolved FLC is preferred over the FLC ratio for monitoring patients with active myeloma. 13 In AL, the FLC response has been found to correlate better with survival than response in M-protein levels in patients with intact immunoglobulins. 14 with serum TnT levels and higher FLC levels were associated with multi-organ involvement and more advanced disease. 15 We showed that the presence of hiFLC even after initial therapy is associated with higher median levels of NT-Pro BNP and ALP, higher rates of cardiac, was associated with improved survival. 15 We also showed that the presence of hiFLC1 and hiFLC2 is correlated with worse PFS and OS in patients with normal FLC ratio after therapy. Palladini et al also demonstrated that the absolute concentration of FLC after therapy had the greatest ability to account for observed deaths, irrespective of baseline FLC level.
12
A major limitation of the serum FLC assay is that the reduction in glomerular filtration in renal insufficiency causes an increase in FLC levels which is asymmetric as j are excreted more readily than k. Due to this reason, there is some suggestion the reference range in this population should be extended to 0.37-3.1. 16 We showed that the prognostic impact of hIFLC1 and hIFLC2 on PFS/OS was independent of serum creatinine. Hence, impaired renal clearance of FLC at the time of achievement of normal FLC ratio was not responsible for the worse survival associated with hiFLC.
The single-center, retrospective nature of our study limits the scope of its conclusions. However, this is the largest known series reported on this patient population to the best of our knowledge. In addition, AL is a rare disease, and large phase 2 or phase 3 prospective studies are difficult to conduct. In conclusion, normalization of iFLC appear to be equally, if not more, relevant than that of FLC ratio in hematological response assessment after first line treatment of patients with AL. This provides unique insight in the prognostic utility of absolute level of FLC in response assessment paving way for its future incorporation in hematological response criteria.
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